Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
histone H3.3-K27M neoantigen vaccine
- Development stage
- Phase 2
- Lead developer
- Beijing Tiantan Hospital
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
**Histone H3.3-K27M neoantigen vaccine** is an investigational therapeutic peptide cancer vaccine developed for newly diagnosed, HLA-A*02-positive diffuse intrinsic pontine glioma harboring the H3.3-K27M mutation. The vaccine presents an H3.3 K27M mutation-derived neoantigen to antigen-presenting cells, with the objective of eliciting mutation-specific CD4-positive and CD8-positive T-cell responses against tumor cells expressing the H3.3-K27M oncohistone. In the Phase 1 ENACTING study, it was administered after biopsy or surgery and conformal radiotherapy, together with the immune adjuvant polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose. The program has been evaluated by Beijing Tiantan Hospital with involvement of TCRCure Biopharma.
- Other names
- Histone H3.3-K27M Neoantigen Vaccine TherapyH3.3-K27M neoantigen vaccineH-3.3-K27M neoantigen vaccineH 3.3-K27M neoantigen vaccine
02
Targets
HLA-A*02:01-H3.3K27M (HLA-A*02:01 presenting the histone H3.3-K27M neoantigen peptide complex)H3.3 (Histone H3.3 Lysine 27 to Methionine Mutant)
Beyond the preview
Go deeper on histone H3.3-K27M neoantigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on histone H3.3-K27M neoantigen vaccine.